These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8083699)

  • 1. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.
    Wishart GC; Bissett D; Paul J; Jodrell D; Harnett A; Habeshaw T; Kerr DJ; Macham MA; Soukop M; Leonard RC
    J Clin Oncol; 1994 Sep; 12(9):1771-7. PubMed ID: 8083699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.
    Jones RD; Kerr DJ; Harnett AN; Rankin EM; Ray S; Kaye SB
    Br J Cancer; 1990 Jul; 62(1):133-5. PubMed ID: 2390473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial.
    Habeshaw T; Paul J; Jones R; Stallard S; Stewart M; Kaye SB; Soukop M; Symonds RP; Reed NS; Rankin EM
    J Clin Oncol; 1991 Feb; 9(2):295-304. PubMed ID: 1988576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
    Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
    Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
    Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
    J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.
    Joensuu H; Holli K; Heikkinen M; Suonio E; Aro AR; Hietanen P; Huovinen R
    J Clin Oncol; 1998 Dec; 16(12):3720-30. PubMed ID: 9850014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
    Piccart MJ; Di Leo A; Beauduin M; Vindevoghel A; Michel J; Focan C; Tagnon A; Ries F; Gobert P; Finet C; Closon-Dejardin MT; Dufrane JP; Kerger J; Liebens F; Beauvois S; Bartholomeus S; Dolci S; Lobelle JP; Paesmans M; Nogaret JM
    J Clin Oncol; 2001 Jun; 19(12):3103-10. PubMed ID: 11408507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
    Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
    J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
    Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
    Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
    Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
    J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
    Lopez M; Vici P; Di Lauro K; Conti F; Paoletti G; Ferraironi A; Sciuto R; Giannarelli D; Maini CL
    J Clin Oncol; 1998 Jan; 16(1):86-92. PubMed ID: 9440727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.
    French Epirubicin Study Group
    J Clin Oncol; 2000 Sep; 18(17):3115-24. PubMed ID: 10963640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
    J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.